
June 26 (Reuters) - CRISPR Therapeutics AG CRSP.BN:
CRISPR THERAPEUTICS REPORTS POSITIVE ADDITIONAL PHASE 1 DATA FOR CTX310™ TARGETING ANGPTL3 AND PROVIDES UPDATE ON IN VIVO CARDIOVASCULAR PIPELINE
CRISPR THERAPEUTICS AG - CTX310 SHOWS UP TO 82% TG AND 86% LDL REDUCTION
CRISPR THERAPEUTICS AG - CTX320 DATA UPDATE EXPECTED IN H1 2026
CRISPR THERAPEUTICS AG - COMPLETE PHASE 1 DATA FOR CTX310 EXPECTED IN H2 2025